Michael Okunewitch
Stock Analyst at Maxim Group
(0.52)
# 4,184
Out of 5,141 analysts
30
Total ratings
23.08%
Success rate
-18.62%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.20 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.29 | +675.19% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.16 | +417.24% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $0.47 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.58 | +5,944.91% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.98 | +140.96% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.57 | +1,683.44% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $0.61 | +2,196.21% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.81 | +65.75% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.60 | +150.00% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.25 | +4,738.71% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.58 | +943.30% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.65 | +1,742.19% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.53 | +1,468.63% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $1.98 | +809.09% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $1.97 | +102,691.88% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.87 | +39.90% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.22 | +2,646.00% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.88 | +544.33% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.71 | +14,004.37% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.20
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.29
Upside: +675.19%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.16
Upside: +417.24%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.47
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.58
Upside: +5,944.91%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.98
Upside: +140.96%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.57
Upside: +1,683.44%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $0.61
Upside: +2,196.21%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.81
Upside: +65.75%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.60
Upside: +150.00%
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.25
Upside: +4,738.71%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.58
Upside: +943.30%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.65
Upside: +1,742.19%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.53
Upside: +1,468.63%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $1.98
Upside: +809.09%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $1.97
Upside: +102,691.88%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.87
Upside: +39.90%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.22
Upside: +2,646.00%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.88
Upside: +544.33%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.71
Upside: +14,004.37%